Drug Information

Drug (ID: DG00804) and It's Reported Resistant Information
Name
Rabeprazole
Synonyms
Rabeprazole; 117976-89-3; Aciphex; Habeprazole; Pariets; 2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; CHEBI:8768; LY307640; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; Rabeprazole [INN:BAN]; 1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole; pariprazole; rabeprazol; Rabeloc; Eraloc; 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-; Rabeprazole (INN); Eraloc (TN); HSDB 7321; 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole; 2-{[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1H-benzimidazole; 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2--1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; LY 307640; CHEMBL1219; SCHEMBL23336; MLS001401446; BIDD:GT0019; GTPL7290; DTXSID3044122; HMS2052P03; HMS3394P03; AMY10338; BCP06638; HY-B0656; BDBM50070209; E-3810 (PPI); MFCD00868879; s4845; STL186112; AKOS015895259; CCG-101158; DB01129; MCULE-7848941080; NC00408; PB21725; 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole; NCGC00388029-07; NCGC00388029-09; AS-34993; SMR000469174; SBI-0206867.P001; DB-020298; DS-002860; FT-0602569; FT-0674301; FT-0674302; Q3515; C07864; D08463; AB00698237-06; 976R893; A803856; SR-01000763041; J-003691; SR-01000763041-3; BRD-A39390670-236-04-0; (R)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; (S)-2-(((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 1H-benzimidazole,2-[(r)-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole; 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]-1H-benzimidazole;Rabeprazole; 2-{[(3-Methyl-4-(3-methoxypropoxy)-2-pyridinyl)methyl]sulphinyl}1H-benzimidazole; 2-{4-(3-Methoxypropoxy)-3-methylpyridine-2-yl}methylsulfinyl-1H-benzimidazole
    Click to Show/Hide
Indication
In total 1 Indication(s)
Bacterial infection [ICD-11: 1A00-1C4Z]
Approved
[1]
Structure
Target Gastric H(+)/K(+) ATPase alpha (ATP4A) ATP4A_HUMAN [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C18H21N3O3S
IsoSMILES
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
InChI
1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
InChIKey
YREYEVIYCVEVJK-UHFFFAOYSA-N
PubChem CID
5029
ChEBI ID
CHEBI:8768
TTD Drug ID
D0KL4J
VARIDT ID
DR01195
DrugBank ID
DB01129
Type(s) of Resistant Mechanism of This Drug
  RTDM: Regulation by the Disease Microenvironment
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Brain cancer [ICD-11: 2A00]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Regulation by the Disease Microenvironment (RTDM) Click to Show/Hide
Key Molecule: Vimentin (VIM) [1]
Molecule Alteration Expression
Up-regulation
 Molecule Info 
Sensitive Disease Glioma [ICD-11: 2A00.1]
 Disease Info 
Experimental Note Discovered Using In-vivo Testing Model
Cell Pathway Regulation AKT/GSK3beta signaling pathway Inhibition hsa04931
NF-KappaB signaling pathway Inhibition hsa04064
In Vitro Model MDA-231 cells Pleural effusion Homo sapiens (Human) CVCL_0062
MJ cells Peripheral blood Homo sapiens (Human) CVCL_1414
MMQ cells Pituitary gland Rattus norvegicus (Rat) CVCL_2117
MOLM-13 cells Peripheral blood Homo sapiens (Human) CVCL_2119
In Vivo Model Male Wistar rats-Stereotaxic glioma model Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis; Gene expression analysis
Experiment for
Drug Resistance		 MTT assay; Scratch wound healing migration assay; Transwell invasion assay
Mechanism Description Epithelial to mesenchymal transition (EMT) is pivotal in embryonic development and wound healing, whereas in cancer it inflicts malignancy and drug resistance. Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. Rabeprazole suppressed EMT by impeding AKT/GSK3beta phosphorylation and/or NF-kappaB signaling and sensitized temozolomide resistance.
Key Molecule: Dishevelled binding antagonist of beta catenin 1 (DACT1) [1]
Molecule Alteration Expression
Up-regulation
 Molecule Info 
Sensitive Disease Glioma [ICD-11: 2A00.1]
 Disease Info 
Experimental Note Discovered Using In-vivo Testing Model
Cell Pathway Regulation AKT/GSK3beta signaling pathway Inhibition hsa04931
NF-KappaB signaling pathway Inhibition hsa04064
In Vitro Model MDA-231 cells Pleural effusion Homo sapiens (Human) CVCL_0062
MJ cells Peripheral blood Homo sapiens (Human) CVCL_1414
MMQ cells Pituitary gland Rattus norvegicus (Rat) CVCL_2117
MOLM-13 cells Peripheral blood Homo sapiens (Human) CVCL_2119
In Vivo Model Male Wistar rats-Stereotaxic glioma model Rattus norvegicus
Experiment for
Molecule Alteration		 Western blotting analysis; Gene expression analysis
Experiment for
Drug Resistance		 MTT assay; Scratch wound healing migration assay; Transwell invasion assay
Mechanism Description Epithelial to mesenchymal transition (EMT) is pivotal in embryonic development and wound healing, whereas in cancer it inflicts malignancy and drug resistance. Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. Rabeprazole suppressed EMT by impeding AKT/GSK3beta phosphorylation and/or NF-kappaB signaling and sensitized temozolomide resistance.
Key Molecule: Glial fibrillary acidic protein (GFAP) [1]
Molecule Alteration Expression
Up-regulation
 Molecule Info 
Sensitive Disease Glioma [ICD-11: 2A00.1]
 Disease Info 
Experimental Note Discovered Using In-vivo Testing Model
Cell Pathway Regulation AKT/GSK3beta signaling pathway Inhibition hsa04931
NF-KappaB signaling pathway Inhibition hsa04064
In Vitro Model MDA-231 cells Pleural effusion Homo sapiens (Human) CVCL_0062
MJ cells Peripheral blood Homo sapiens (Human) CVCL_1414
MMQ cells Pituitary gland Rattus norvegicus (Rat) CVCL_2117
MOLM-13 cells Peripheral blood Homo sapiens (Human) CVCL_2119
In Vivo Model Male Wistar rats-Stereotaxic glioma model Rattus norvegicus
Experiment for
Molecule Alteration		 Western blotting analysis; Gene expression analysis
Experiment for
Drug Resistance		 MTT assay; Scratch wound healing migration assay; Transwell invasion assay
Mechanism Description Epithelial to mesenchymal transition (EMT) is pivotal in embryonic development and wound healing, whereas in cancer it inflicts malignancy and drug resistance. Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. Rabeprazole suppressed EMT by impeding AKT/GSK3beta phosphorylation and/or NF-kappaB signaling and sensitized temozolomide resistance.
References
Ref 1 Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition .Cell Oncol (Dordr). 2021 Aug;44(4):889-905. doi: 10.1007/s13402-021-00609-w. Epub 2021 May 4. 10.1007/s13402-021-00609-w

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.